Mycobacterium Avium Complex Pulmonary Disease
Conditions
Keywords
Pharmacokinetics, Minocycline, Rifampicin
Brief summary
Antimycobacterial treatment of M. avium complex pulmonary disease (MAC-PD) has suboptimal cure rates and is challenging due to frequent adverse drug reactions and drug-drug interactions. Hence, there is an urgent need for improved treatment regimens with effective and tolerable antibiotics. Minocycline is a well-tolerated, orally administered tetracycline-type antibiotic with in vitro activity against MAC, but pharmacokinetic data in the target population is lacking. Moreover, rifampicin, a strong inducer of cytochrome P450 enzymes involved in drug metabolism and of various drug transporters, is part of the current first-line MAC-PD treatment regimen and has a substantial interaction with doxycycline, a related tetracycline. Pharmacokinetic data in the target population will allow us to propose an appropriate dose of minocycline when co-administered with or without rifampicin Mino-PK is an open label, one-arm, two-period, fixed-order pharmacokinetic study that will assess exposure to minocycline in MAC-PD patients with and without concurrent use of rifampicin. Subjects will receive two 5-day dosing periods of minocycline; the first without and second with concurrent use of rifampicin. Minocycline plasma concentrations will be determined after both dosing periods.
Interventions
DRUGMinocycline
Patients with M. avium complex pulmonary disease will receive 200 mg of minocycline for 5 days before starting rifampicin and after 1 month (±1 week) of receiving rifampicin. Antimycobacterial drugs other than rifampicin can be started prior to or simultaneous with the first minocycline dosing period as part of standard care. At day 5 of both minocycline dosing periods, blood will be sampled for minocycline plasma concentration measurements at T = 0, 1, 2, 3, 4, 6, 8 and 24 hours.
Sponsors
Radboud University Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A single group, two-period, fixed-order pharmacokinetic study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 2020 guideline (ATS/ERS/ESCMID/IDSA) diagnostic criteria for nontuberculous mycobacterial pulmonary disease are met, i.e. the patient is symptomatic, has nodules, bronchiectasis or fibro-cavitary lesions seen on (HR)CT scan of the lungs and ≥2 positive sputum cultures or one positive bronchoalveolar lavage culture of the same M. avium complex species. * At least one of the positive cultures must be done in the last 4 months before inclusion. * The subject is eligible to start the guideline-recommended rifampicin-based regimen according to the treating physician. * Age ≥ 18 years. * Signed and dated patient informed consent.
Exclusion criteria
* A relevant medical history or current condition that might interfere with drug absorption, distribution, metabolism or excretion (i.e. chronic gastro-intestinal disease, renal or hepatic disease). * Diagnosed with cystic fibrosis (as this may affect the pharmacokinetics of drugs). * Pregnant or breastfeeding (contra-indications for minocycline) or inadequate contraceptive measures (in view of the administration of rifampicin which interacts with oral contraceptive drugs, adequate contraceptive measures are abstinence from sexual activities and barrier methods). * Use of drugs that cause a relevant drug interaction with minocycline, i.e. oral magnesium, , bismuth, aluminium, calcium, zinc or iron containing formulations, antacid drugs and drugs besides rifampicin that are strong inducers of metabolic enzymes, including barbiturates, carbamazepin and phenytoin (as judged by the investigators). * ALAT \> 3 times the upper limit of normal (normal \<45 U/l). * ASAT \> 3 times the upper limit of normal (normal \<35 U/l). * An abnormal serum creatinine level (defined as a level that is higher than the upper limit of normal, i.e. \>110 umol/l). * Active alcohol abuse. * Hypersensitivity to minocycline or to other tetracycline antibiotics.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic parameters of minocycline in MAC-PD patients without concurrent use of rifampicin. | Day 5 of the first minocycline dosing period | The area under the curve (AUC0-24h) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic parameters of minocycline in MAC-PD patients with concurrent use of rifampicin. | Day 5 of the second minocycline dosing period | The area under the curve (AUC0-24h) |
| Pharmacokinetic parameters of rifampicin in MAC-PD patients | Day 5 of the second minocycline dosing period | The peak plasma concentration (Cmax) |
| Adverse Events | Through study completion, an average of 6 weeks | The number of (participants with) adverse events will be measured. Adverse events will be graded according to the 'Common Terminology Criteria for Adverse Events' (CTCAE) |
Countries
Netherlands
Outcome results
None listed